is There Any Evidence-based Medicine for the Very Old?

More documents

Recommendations

Info

Event free Survival % 100 90 80 70 60 50 SENIORS Trial: All Cause Mortality or CV Hospital Adm<strong>is</strong>sion (Primary Outcome) Nebivolol Placebo Hazard Ratio 0.86 [0.74;0.99] p = 0.039 0 6 12 18 24 30 36 Time (months) No. of events: Nebivolol 332 (31.1%); Placebo 375 (35.3%)
LVEF 35 % > 35 % Age 70-75 y > 75 y Total Death or CV Hospital<strong>is</strong>ation by Subgroup Nebivolol 219 (32.1%) 110 (28.9%) 148 (27.5%) 184 (34.8%) 332 (31.1%) Placebo 249 (36.3%) 125 (33.6%) 176 (33.5%) 199 (37.1%) 375 (35.3%) Favours Nebivolol Hazard ratio and 95% CI Favours Placebo 0.50 0.60 0.70 0.80 0.90 1.00 1.10 1.20
Page 1 and 2: Heart Failure 2005 The octogenarian
Page 3 and 4: Mean Age of the Patients with Heart
Page 5 and 6: Factors Distinguishing HF in the El
Page 7 and 8: Baseline Characteristics of Patient
Page 9 and 10: % of patients 35 30 25 20 15 10 5 0
Page 11 and 12: Probability Non-cardiac Comorbidity
Page 13 and 14: Management of HF in the Elderly: Ge
Page 15 and 16: Pharmacological therapy of heart fa
Page 17 and 18: Drug ACEi Loop diuretics Beta-block
Page 19 and 20: Elderly Age is an Independent Predi
Page 21 and 22: Effects of ACE inhibitors on outcom
Page 25 and 26: BRING UP Reasons for Not Commencing
Page 27 and 28: % 100 75 50 25 0 84.3 70- 80 years
Page 29 and 30: % Effect of Bisoprolol on Mortality
Page 31 and 32: Beta-blockers Reduce Mortality also
Page 33: SENIORS: Baseline Characteristics A
Page 39 and 40: Drug ACEi Loop diuretics Beta-block
Page 41 and 42: 10 5 0 -5 -10 -15 -20 -25 -30 -35 L
Page 43 and 44: % 40 30 20 10 Lack of effect of age
Page 45 and 46: Randomised Controlled Trial of Card
Page 47 and 48: Randomized Controlled Trial of Spec
Page 49: Efficacy of Disease Management Prog

is There Any Evidence-based Medicine for the Very Old?

Create successful ePaper yourself

Delete template?

Save as template?